Stockreport

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

AbCellera Biologics Inc. - Common Shares  (ABCL) 
PDF VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that it will disclose interim results from the Phase 1 portion of its study of [Read more]